Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Globus Medical Inc (NYSE: GMED) closed at $88.36 in the last session, down -0.06% from day before closing price of $88.41. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 0.77 million shares were traded. GMED stock price reached its highest trading level at $89.12 during the session, while it also had its lowest trading level at $88.22.
Ratios:
We take a closer look at GMED’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.52. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 4.13. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 07, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $91.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 12 ’25 when Norwalk Leslie V sold 4,000 shares for $88.85 per share. The transaction valued at 355,400 led to the insider holds 12,419 shares of the business.
Norwalk Leslie V bought 4,000 shares of GMED for $355,000 on Dec 12 ’25. On Dec 01 ’25, another insider, Kline Kyle, who serves as the Senior Vice President, CFO of the company, sold 18,542 shares for $90.00 each. As a result, the insider received 1,668,780 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 11933658112 and an Enterprise Value of 11555619840. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.56, and their Forward P/E ratio for the next fiscal year is 21.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.29 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 4.172 whereas that against EBITDA is 14.451.
Stock Price History:
The Beta on a monthly basis for GMED is 1.06, which has changed by 0.06891549 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 11.10%, while the 200-Day Moving Average is calculated to be 33.32%.
Shares Statistics:
According to the various share statistics, GMED traded on average about 1.73M shares per day over the past 3-months and 1414720 shares per day over the past 10 days. A total of 112.18M shares are outstanding, with a floating share count of 111.35M. Insiders hold about 17.28% of the company’s shares, while institutions hold 88.30% stake in the company. Shares short for GMED as of 1765756800 were 4097040 with a Short Ratio of 2.37, compared to 1763078400 on 4824835. Therefore, it implies a Short% of Shares Outstanding of 4097040 and a Short% of Float of 4.1199997.
Earnings Estimates
Investors are keenly observing as 13.0 analysts analyze and rate. The current performance of Globus Medical Inc (GMED) in the stock market.The consensus estimate for the next quarter is $0.9, with high estimates of $0.98 and low estimates of $0.79.
Analysts are recommending an EPS of between $3.82 and $3.76 for the fiscal current year, implying an average EPS of $3.79. EPS for the following year is $4.12, with 13.0 analysts recommending between $4.3 and $3.85.
Revenue Estimates
According to 12 analysts,. The current quarter’s revenue is expected to be $778.31M. It ranges from a high estimate of $788.6M to a low estimate of $767.5M. As of. The current estimate, Globus Medical Inc’s year-ago sales were $657.29MFor the next quarter, 12 analysts are estimating revenue of $725.83M. There is a high estimate of $749.8M for the next quarter, whereas the lowest estimate is $698.93M.
A total of 13 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.9B, while the lowest revenue estimate was $2.88B, resulting in an average revenue estimate of $2.89B. In the same quarter a year ago, actual revenue was $2.52BBased on 13 analysts’ estimates, the company’s revenue will be $3.12B in the next fiscal year. The high estimate is $3.16B and the low estimate is $3.06B.
